Search Results
2. Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials
3. Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study
4. Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings
5. DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers
6. Elevated GM3 plasma concentration in idiopathic Parkinson’s disease: A lipidomic analysis
7. Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease
8. Psychiatrists’ Views of the Genetic Bases of Mental Disorders and Behavioral Traits and Their Use of Genetic Tests
9. Use of Genetic Tests among Neurologists and Psychiatrists: Knowledge, Attitudes, Behaviors, and Needs for Training
10. Attitudes and Practices Among Internists Concerning Genetic Testing
11. Lessons from Epidemiologic Research about Risk Factors, Modifiers, and Progression of Late Onset Alzheimer’s Disease in New York City at Columbia University Medical Center
12. Lessons from Epidemiologic Research about Risk Factors, Modifiers, and Progression of Late Onset Alzheimer’s Disease in New York City at Columbia University Medical Center
13. Views of internists towards uses of PGD
14. Genome-Wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population
15. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease
16. Seizures in Alzheimer Disease. Who, When, and How Common?
17. The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's disease
18. Mild Parkinsonian signs are associated with lower olfactory test scores in the community-dwelling elderly
19. Quantitative brain measurements in community-dwelling elderly persons with mild parkinsonian signs
20. Risk of Parkinson disease in carriers of parkin mutations : estimation using the kin-cohort method
21. An Evaluation of Neurocognitive Status and Markers of Immune Activation as Predictors of Time to Death in Advanced HIV Infection
22. Decision‐Making About Reproductive Choices Among Individuals At‐Risk for Huntington's Disease
23. Disclosures of Huntington disease risk within families: Patterns of decision‐making and implications
24. Impairment of Nonverbal Recognition in Alzheimer Disease: A Pet O-15 Study
25. Mild parkinsonian signs and plasma homocysteine concentration in community-dwelling elderly individuals
26. The roles of family members, health care workers, and others in decision-making processes about genetic testing among individuals at risk for Huntington disease
27. An Observational Study of Cognitive Impairment in Amyotrophic Lateral Sclerosis
28. Case-control study of the parkin gene in early-onset Parkinson disease
29. Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study
30. Incidence and Predictors of Seizures in Patients with Alzheimer's Disease
31. A 10-item smell identification scale related to risk for Alzheimer's disease
32. Delusions and Hallucinations Are Associated With Worse Outcome in Alzheimer Disease
33. Motor Signs Predict Poor Outcomes in Alzheimer Disease
34. Attenuated Central Nervous System Infection in Advanced HIV/AIDS With Combination Antiretroviral Therapy
35. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia: Lewy Body Dementia vs. AD and PD-Dementia
36. Motor Signs During the Course of Alzheimer Disease
37. Association of Life Activities With Cerebral Blood Flow in Alzheimer Disease: Implications for the Cognitive Reserve Hypothesis
38. Inter-Rater Reliability of a Clinical Staging of HIV-Associated Cognitive Impairment
39. Medication Management Skill in HIV: I. Evidence for Adaptation of Medication Management Strategies in People with Cognitive Impairment. II. Evidence for a Pervasive Lay Model of Medication Efficacy
40. Psychopathological Features in Alzheimer's Disease: Course and Relationship with Cognitive Status
41. The Neuropsychological Profiles of Mild Alzheimer's Disease and Questionable Dementia as Compared to Age-Related Cognitive Decline
42. The Rate of Cognitive Decline and Risk of Reaching Clinical Milestones in Alzheimer Disease
43. Where do Perseverations Come From?
44. Combined Effect of Age and Severity on the Risk of Dementia in Parkinson's Disease
45. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study
46. HIV-Associated Cognitive Impairment before and after the Advent of Combination Therapy
47. Longitudinal Assessment of Patient Dependence in Alzheimer Disease
48. Memory and Executive Function Impairment Predict Dementia in Parkinson's Disease
49. The Association of Incident Dementia with Mortality in PD
50. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease
- « Previous
- Next »
- 1
- 2
- 3